11
total announcements
524372.BO · 15 min delayed
Orchid Pharma Ltd
Orchid Pharma Ltd has announced the schedule of Analysts/Investors Earning Call for the Quarter-1 ended on June 30, 2026, to discuss the financial results/ performance of the Company.
Orchid Pharma Ltd
Orchid Pharma Ltd has filed a statement of deviation or variation for the quarter ended June 30, 2026, on the use of proceeds of funds raised through Qualified Institutional Placement (QIP). The company has modified the allocation of QIP proceeds due to changes in the business environment and to meet current strategic requirements.
Orchid Pharma Ltd
Orchid Pharma Ltd has released a Monitoring Agency Report for Q1 FY 2026-27, showing no deviation from the objects of the QIP issue. The report was issued by CARE Ratings Limited and covers the utilization of proceeds raised through the Qualified Institutions Placement.
Orchid Pharma Ltd
Orchid Pharma Ltd has announced revised audited financial results for the year ended March 31, 2026, following a scheme of merger with Dhanuka Laboratories Ltd. The company's net sales and total income have increased, while expenses have also risen. The profit before tax stands at ₹3,266.29 lakhs.
Orchid Pharma Ltd
Orchid Pharma Ltd has announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, showing a net profit of ₹1,193.72 lakhs and ₹3,266.29 lakhs respectively.
Orchid Pharma Ltd
Orchid Pharma Ltd's board meeting approved unaudited financial results for Q1 FY 2026-27, ended June 30, 2026, with a net profit of ₹1,193.72 lakhs.
Orchid Pharma Ltd
Orchid Pharma Ltd has informed BSE that the meeting of the Board of Directors is scheduled on 14/08/2026 to consider and approve Unaudited Limited reviewed financial results for the quarter ended June 30, 2026.
Orchid Pharma Ltd
Orchid Pharma Ltd has informed about the allotment of 4,45,86,052 equity shares to eligible shareholders of Dhanuka Laboratories Ltd as part of the scheme of amalgamation.
Orchid Pharma Ltd
Orchid Pharma Ltd has informed that its Board of Directors has approved the issuance and allotment of 4,45,86,052 fully paid-up equity shares to eligible shareholders of Dhanuka Laboratories Ltd as part of the scheme of amalgamation. The shares will be listed and traded on BSE and NSE and will rank pari-passu with existing equity shares.
Orchid Pharma Ltd
Orchid Pharma Ltd has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/08/2026, inter alia, to consider and approve prior intimation of board meeting.
Orchid Pharma Ltd
Orchid Pharma Ltd has announced an Investor Roadshow scheduled to be held in Singapore on July 29-31, 2026. The event will be attended by Mr. Mridul Dhanuka, Whole Time Director of the Company. No unpublished price sensitive information will be shared during the meet.